AMRN
Amarin Corporation plc
NASDAQ · Healthcare · Biotechnology · IE
$13.63
−0.58%Year over year
Reported trailing growth
- Revenue
- -15.1%
- EBITDA
- +70.6%
- EBIT
- +69.8%
- EPS
- +71.6%
- Free cash flow
- +526.4%
- Operating cash flow
- +526.4%
Forward estimates
Based on analyst estimates
- Revenue
- -7.4%
- EBITDA
- +93.0%
- EPS
- +87.8%
Three-year CAGR
- Revenue
- -16.7%
- EBITDA
- +55.5%
- EBIT
- +84.8%
- Net income
- +52.8%
- EPS
- +55.0%
- Free cash flow
- -1.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026